MUC1- and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin-2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model.

摘要: DNA vaccination is a promising cancer treatment due to its safety, but poor immunogenicity limits application. However, immunoadjuvants, heterogeneous prime-boost strategies and combination with conventional treatments can be used improve the antitumour immune effects. A CpG motif interleukin-2 (IL-2) cytokine are often as adjuvants. In this study, vaccine containing was constructed evaluate adjuvant effect. The results show that cytotoxicity of increased fivefold, survival lifetime prolonged twofold by adjuvant. To simplify industrial production process, bicistronic plasmid carry fusion genes survivin/MUC1 (MS) IL-2 in backbone. showed effect same two co-injected regime. Furthermore, could suppress metastatic tumour foci 69.1% colorectal carcinoma-bearing mice. Moreover, induced survivin- MUC1-specific responses splenocytes promoting factor CCL-19 GM-CSF upregulated, while metastatic-associated MMP-9 immunosuppressing PD-L1 downregulated tissue. When combining chemotherapy drug oxaliplatin, about 2.5-fold. conclusion, form good effects on inhibiting both growth metastasis, oxaliplatin